Method of treating bovine digital dermatitis (dermatitis digitalis)
SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.
EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.
The invention relates to veterinary medicine, in particular to the drugs used in the treatment of purulent-necrotic lesions of the distal limbs of cattle, which include finger dermatitis.
This disease is distributed worldwide and causes great damage to the dairy livestock. Finger dermatitis in cattle affects mainly cows, located most often on the skin of the arch mercapital slit in the rear limbs in the form of rounded erosion size 1-5 cm [Catch A.A. Disease hooves and finger cattle / AA of Traps, SERGEY Lopatin; Grew up. Acad. C. agricultural Sciences. Sib. the region separa-tion. Inst. of the experimental. veterinary science of Siberia and the Far East. -Novosibirsk, 2010. - P80-95]. In the last decade, the number of animals affected finger dermatitis of cattle in Russia has increased dramatically.
There is an ointment for the treatment of wounds [EN 2035183C1, A61K35/78, A61K35/78, A61K31/00, 20.05.1995] in farm animals, which includes copper sulphate. It promotes rapid healing of wounds. However, information regarding the use of this ointment for the treatment of digital dermatitis in cattle in the available literature sources not found.
The closest analogue is zinc Ointment [Gulenko V.N., Volkov, I., Usha BV General and clinical wind is stationary recipe: a Handbook/ edited Prof. Gulenko NR. -2nd ed. -M.: Kolos, 2000. - S. 161], which in its composition contains zinc oxide 10%, the rest - ointment basis. Zinc ointment astringent, drying, anti-inflammatory and disinfectant action. Use this ointment for skin diseases (weeping wounds, burns, dermatitis, furunculosis, pyoderma, bedsores and other). Data on the use of zinc ointment against digital dermatitis in cattle was not found.
The task of the invention is the creation of the drug in the form of creams for effective treatment of digital dermatitis in cattle.
This is achieved by the preparation of a drug for the treatment of digital dermatitis in cattle in the form of ointments, containing the following components in proportions, wt.%:
|zinc oxide||9 - 11|
|copper sulphate||35 - 45|
Drug for the treatment of digital dermatitis in cattle in the form of ointment has antibacterial effect on pathogens of digital dermatitis in cattle, as well as anti-inflammatory, drying and nanosail the shining effect.
Drug for the treatment of digital dermatitis in cattle in the form of an ointment is prepared by mixing to obtain a homogeneous mass.
Drug for the treatment of digital dermatitis in cattle in the form of ointment is a homogeneous viscous mass of blue color.
Drug for the treatment of digital dermatitis in cattle in the form of ointments applied by coating on the affected areas of skin. Enough 1-2 applications.
All components used drug for the treatment of digital dermatitis in cattle in the form of ointments are not expensive and widely available on the modern market of veterinary drugs, i.e. the invention can be used in almost every household.
An example of a drug for the treatment of digital dermatitis in cattle in the form of ointments with different concentrations of copper sulphate.
|The concentration of copper sulphate, wt.%||In the treated heads||The ratio of broad-spectrum drug, time||The duration of treatment, days||Notes|
|55||3||1||-||After application of the ointment animal has severe anxiety|
Technical and economic efficiency of the drug for the treatment of digital dermatitis in cattle in the form of ointment is effective treatment for digital dermatitis in cattle.
SOURCES of INFORMATION
1. The traps A.A. Disease hooves and finger cattle./ A.A. of Traps, SERGEY Lopatin; Grew up. Acad. C. agricultural Sciences. Sib. the region separa-tion. Inst. of the experimental. veterinary science of Siberia and the Far East. - Novosibirsk, 2010. - S. 80-95.
2. EN 2035183 C1 IPC6A61K 35/78, A61K 31/00, 20.05.1995.
1. Gulenko V.N., Volkov, I., Usha BV General and clinical veterinary compounding: a Handbook/ edited by Prof. Gulenko NR. -2nd ed. -M.: Kolos, 2000. -S. 161.
Drug for the treatment of digital dermatitis big horn the cattle in the form of ointment,
consisting of a filler containing ointment base, and the active ingredient is zinc oxide, characterized in that the active substance further comprises copper sulphate in the following ratio, wt.%:
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for the preoperative preparation of the patients suffering a perforated nasal septum. Intranasal silicone splints are placed 10 days before the operation. The splint is incised from one side within a perforation border. A 30° endoscope is used to assist a 7-day daily nasal perforation rinsing with chlorhexidine. A suction unit is used to evacuate mucosal secretion; synthomycin ointment is introduced through the incision in the silicone splint to the perforation region. The nasal cavity is irrigated daily with antiseptic and vasoconstrictive preparations. On the 7th day, the intranasal splints are removed.
EFFECT: method enables relieving the mucosal inflammation within the perforation, promotes the prolonged drug retention in the introduction place, ensures avoiding an overlay of a secondary infection, improves the functional state of ciliated epithelium.
SUBSTANCE: invention refers to medicine, namely to surgical dentistry and maxillofacial surgery, and is applicable in maxillary sinusotomy with fistula repair. A mucous membrane is incised to a bone under an intubation narcosis after a two-fold preparation of a surgical area. A D-shaped flap is cut out within an alveolar socket of an extracted tooth to be extended along a mucobuccal fold of an upper jaw on one side to a second incisor, and on the other side - to a third molar. The flap together with the periosteum is separated and retracted upwards with exposing a canine fossa and the alveolar socket of the extracted tooth. A hole is created within the canine fossa. Pathologically changed tissues or all sinus mucosa is scooped with a bone curette through the created hole. The alveolar socket of the extracted tooth is inspected. After the cavity has been scooped, an artificial hole is created towards a nasal cavity through an inferior nasal meatus. The sinus cavity is packed with a iodoform cotton swab; an end of the cotton swab is laid thoroughly on a sinus bottom, namely within the defect; the end of the cotton swab is brought out into a nose. A mucoperiosteal flap is mobilised within the alveolar socket of the extracted tooth, laid on the alveolar socket; the wound is closed completely. In the postoperative period, the cotton swab is removed from the sinus on the 9-10th day. The sutures are removed on the 10-11th day.
EFFECT: method enables reducing an incidence of recurrent oroantral communications in the postoperative period ensured by a compact packing of the sinus, and the antiseptic and regeneration effect of iodoform on the maxillary sinus.
SUBSTANCE: invention relates to veterinary science, namely to obstetrics and gynaecology. A preparation for treating and preventing sub-clinical, clinical, acute and chronic mastitis in farm and domestic animals contains an active substance that is - triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide and a pharmaceutically acceptable carrier that is Vaseline in ratio 1:2000.
EFFECT: invention provides the higher antimicrobial effectiveness and the lower toxicity of the ointment with the lower concentration of the active substance.
3 tbl, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture.
EFFECT: preparing the antiseptic drug with haemostatic action for wound cleaning.
2 cl, 9 ex
SUBSTANCE: invention refers to pharmaceutical industry and represents a preparation possessing the anti-inflammatory action, stimulating the mucosa regeneration, and containing magnesium-chloride mineral bischofit brine 1.27±0.01 g/ml with normalised specific gravity, slastiline, menthol, thymol, and a stabilising agent differing by the fact that it contains magnesium-chloride mineral bischofit brine free from technogenic impurities, with the ingredients in the preparation are taken in specific proportions, g.
EFFECT: reducing acute daily oral toxicity in 1,7-1,9 times.
SUBSTANCE: invention refers to derivatives of oxazolopyrimidine in any of their stereoisomeric forms, or in the form of a mixture of stereoisomeric forms specified in Claim 1.
EFFECT: oxazolopyrimidine derivatives having agonistic activity in relation to Edg-1 receptor.
5 tbl, 319 ex
SUBSTANCE: invention relates to medicine, namely to general surgery, and can be applied in prevention of purulent-inflammatory complications of anterior abdominal wall wounds in case of strangulated ventral hernias. For this purpose, 10% solution of colloidal nanosilver is introduced into operation wound after elimination of strangulation, with preliminary injections on perimetre of hernial orifice edges in dose 0.1 ml of solution per 1 cm2 of aponeurosis. After that, after fixation of synthetic implant, injections are made along the line of sutures on periphery in dose 0.1 ml per 1 cm2 of suture. After that, subcutaneous adipose cellular tissue is infiltrated with solution of colloidal nanosilver in dose 0.1 ml of solution per 1 cm2 of wound.
EFFECT: method ensures considerable reduction of risk of development of purulent-inflammatory complications in patients with said pathology, as well as acceleration of processes of tissue reparation due to application of biologically active colloidal solution of nanosilver, producing selective impact only on pathogenic microorganisms, on all layers of anterior abdominal wall and zone of synthetic implant fixation.
5 cl, 1 ex
SUBSTANCE: invention refers to medicine, namely purulent surgery, and may be used for treating infected wounds. That is ensured by surgical treatment of suppurative focuses and exsection of necrotised tissues. Then the whole wound surface is treated with 10% colloidal nanosilver. The subcutaneous fat is infiltrated with 10% colloidal nanosilver at 0.1 ml of the solution per 1 cm2 of the wound. Additionally, the wound is covered with a sterile 10% colloidal nanosilver wipe.
EFFECT: method enables reducing the length of wound granulation and epithelisation ensured by using the biologically active colloidal nanosilver solution coating all wound layers and rendering selective action on pathogens only.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, specifically to an agent showing antimicrobial activity.
EFFECT: agent possessing antimicrobial action and representing robinia (Robinia pseudaacacia L) seed essence prepared by collecting the seeds in October and extracting them three times in petroleum benzene under certain conditions.
2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, particularly to ophthalmology. One of the objects is using 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diole (compound A), its separate isomers and a mixture of the same isomers, or pharmaceutically acceptable salts, solvates and hydrates thereof for preparing an agent for treating keratoplasty or refractive keratoplasty consequences. The second object is a method of treating the keratoplasty or refractive keratoplasty consequences in an individual in need thereof that involves administering a therapeutically effective amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diole (compound A), its separate isomers and mixtures of the same, pharmaceutically acceptable salts, solvates and hydrates thereof into the above individual.
EFFECT: invention provides treating the eye disorder consequences.
SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.
EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.
1 tbl, 1 ex
SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method.
EFFECT: inventions make it possible to increase step-by-step output of the hepatocyte growth factor, with the hepatocyte growth factor being concentrated in eluate in the presence of AT-III.
26 cl, 2 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues.
EFFECT: pharmaceutical composition is effective for dehydration, atrophy and removal of abnormal tissues in treating haemorrhoids, haemangiomas, varicose veins, burns, bleeding traumatic wounds, local wounds caused by chemicals or microorganisms.
9 cl, 12 dwg, 2 tbl, 7 ex
SUBSTANCE: affected areas of skin are coated with dressings impregnated with therapeutic preparations containing 1.0-2.0% hypromellose, an antiseptic specified in a group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron and 2% lidocaine hydrochloride. At the stage of wound exudation on the second or third post-injury day, the dressings impregnated with 2.0% hypromellose, the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron, and 2% lidocaine hydrochloride are used and changed once a day. At the stage of proliferation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 2 days. At the stage of epithelisation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 3 days until the wound surface is completely epithelised.
EFFECT: invention provides the humid environment on the burn wound surface which stimulates wound epithelisation and prevents the infectious complications.
FIELD: chemistry, pharmacology.
SUBSTANCE: pharmacological composition for preparing drug forms in form of powder, solution or bandage consists of biocompatible film-generating polymer polyvinylpyrrolidone (Mm 20000), iodine and Novocain, taken in quantities, given in the invention formula. Pharmaceutical composition is intended for processing wound surface and treatment of burns. Composition possesses antiseptic, local anesthetic and wound-healing action.
EFFECT: water-soluble form of medication possesses high anti-burn activity, low cost and long storage term.
SUBSTANCE: invention relates to compound of formula , where Z stands for phenyl, substituted with 1-5 halogen atoms, selected from fluorine and chlorine; R4 stands for C1-C4-alkyl with linear chain or C3-C4-alkyl with branched chain; or to its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, inhibiting prolyl hydroxylase activity, based on said compounds.
EFFECT: obtained are novel compounds and based on them pharmaceutical composition, which can be applied in medicine for treatment of diseases, associated with immune response of organism.
18 cl, 20 dwg, 8 tbl, 13 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient.
EFFECT: invention is intended for prevention and/or treatment of wrinkles in the area of eyes and mouth angles, small wrinkles, eye bags and dark circles under eyes.
22 cl, 2 ex, 11 tbl
SUBSTANCE: invention relates to a wound-healing drug which consists of stearic acid; castor oil; zinc stearate; 70% alcohol extract of a plant collection including oak tree bark, marigold flowers, wild chamomile flowers, nettle leaves, taken in ratio of 1:3:2:1, respectively; Na salts of fatty acids of wool fat; boric acid; vaseline; glycerine; triethanolamine; treated water; vegetable oil; Tipton weed extract; wild rose oil or sea buckthorn oil; 10% propolis oily solution; natural L-amino acid-peptide biocomplex obtained by extracting native paunch manure of ruminants with 2.0-3.0% NaCl solution; purified lanolin and derivatives thereof.
EFFECT: improved bactericidal, anti-inflammatory, regenerating, antioxidant and antimicrobial properties, drug does not have allergic action.
SUBSTANCE: composition contains the bactericidal substance Poviargol in the amount of 2.1-7.0 wt % and zosterin in the amount of 1.1-7.0 wt %.
EFFECT: synergetic action of the ingredients of the composition and promotion of the anti-inflammatory, radio protective, reparative action.
SUBSTANCE: invention refers to using ultradisperse silver-containing systems as anti-inflammatory, anti-exudative and wound-healing agents. The ultradisperse silver-containing systems represent zero-valent silver metal nanocomposites at particle size 10-25 nm stabilised with arabinogalactine and its sulphated derivative. The invention also refers to an agent for wound and burn healing having anti-inflammatory, anti-exudative, wound-healing and antimicrobial activity, comprising said silver nanocomposites as a pharmacologically active substance and additionally containing carbomer, triethanolamine, glycerol or 1,2-propylene glycol and water. The agent is presented in the form of topical hydrophilic gel. The invention also refers to using the above agent for wound and burn healing in an individual in need thereof.
EFFECT: declared invention provides creating the hydrophilic gels of silver nanocomposites that are applicable for wound and burn healing.
3 cl, 8 dwg, 7 ex
SUBSTANCE: invention refers to the veterinary science and is applicable for treating bovine digital dermatitis. A method involves applying a preparation in the form of an ointment of the following formulation, wt %: veterinary copper sulphate 35-45, zinc oxide 9-11, an ointment base - the rest. The preparation is made by mixing the ingredients until smooth. The preparation is applied on the involved regions 1-2 times with or without a protective dressing.
EFFECT: method is effective in treating bovine digital dermatitis.
1 tbl, 1 ex